Lack of efficacy of a third tumour necrosis factor α antagonist after failure of a soluble receptor and a monoclonal antibody

Rheumatology

Volumn 45, Issue 9, 2006, Pages 1121-1124

  Solau Gervais, E ^a   Laxenaire, N ^a   Cortet, B ^a   Dubucquoi, S ^a   Duquesnoy, B ^a   Flipo, R M ^a  

^a UNIV LILLE   (France)

Author keywords

Adalimumab; Anti TNF agent; Etanercept; Infliximab; Rheumatoid arthritis; Switch

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ARTICLE; CLINICAL PROTOCOL; COHORT ANALYSIS; DISEASE ACTIVITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SKIN MANIFESTATION;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33748123744     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel054     Document Type: Article

References (21)

1. Klinkhoff A. Biological agents for rheumatoid arthritis: Targeting both physical function and structural damage. Drugs 2004;64: 1267-83.
2. Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
3. Moreland LW, Cohen SB, Baumgartner SW et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001;28:1238-44.
4. Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003;48:35-45.
5. Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2003;62(Suppl. 2):iI13-ii16.
6. Bathon JM, Genovese MC. The Early Rheumatoid Arthritis (ERA) trial comparing the efficacy and safety of etanercept and methotrexate. Clin Exp Rheumatol 2003;21(5 Suppl. 31):S195-7.
7. St Clair EW, van der Heijde DM, Smolen JS et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial. Arthritis Rheum 2004;50:3432-43.
8. Calabrese LH. Molecular differences in anticytokine therapies. Clin Exp Rheumatol 2003;21:241-8.
9. Schwartzman S, Fleischmann R, Morgan GJ, Jr. Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis? Arthritis Res Ther 2004;6(Suppl. 2):S3-S11.
10. Hansen KE, Hildebrand JP, Genovese MC et al. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol 2004;31:1098-102.
11. Haraoui B, Keystone EC, Thorne JC et al. Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J Rheumatol 2004;31:2356-9.
12. Ang HT, Helfgott S. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor alpha antagonists in patients with rheumatoid arthritis? J Rheumatol 2003;30:2315-8.
13. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
14. van der Heijde DM, van't Hof M, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993;20:579-81.
15. Brocq O, Plubel Y, Breuil V et al. Etanercept-infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti TNFalpha. Presse Med 2002;31(39 Pt 1):1836-9.
16. Gomez-Puerta JA, Sanmarti R, Rodriguez-Cros JR, Canete JD. Etanercept is effective in patients with rheumatoid arthritis with no response to infliximab therapy. Ann Rheum Dis 2004;63:896.
17. van Vollenhoven R, Harju A, Brannemark S, Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann Rheum Dis 2003;62:1195-8.
18. Yazici Y, Erkan D. Do etanercept-naive patients with rheumatoid arthritis respond better to infliximab than patients for whom etanercept has failed? Ann Rheum Dis 2004;63:607-8; author reply 608.
19. Brocq O, Albert C, Roux C, Gerard D, Breuil V, Ziegler LE. Adalimumab in rheumatoid arthritis after failed infliximab and/or etanercept therapy: experience with 18 patients. Joint Bone Spine 2004;71:601-3.
20. Bennett AN, Peterson P, Zain A, Grumley J, Panayi G, Kirkham B. Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure. Rheumatology 2005; 44:1026-31.
21. Combe B. Switching between anti-TNFalpha agents: What is the evidence? Joint Bone Spine 2004;71:169-71.